Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: maize starch; colloidal anhydrous silica; purified talc; pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 400 mg - capsule - excipient ingredients: maize starch; pregelatinised maize starch; purified talc; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 0.511 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; shellac; isopropyl alcohol; ethanol absolute; butan-1-ol; propylene glycol; strong ammonia solution; iron oxide black; potassium hydroxide; purified water; titanium dioxide; iron oxide yellow; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; microcrystalline cellulose; medium chain triglycerides; titanium dioxide; magnesium stearate; maize starch; stearic acid; lactose monohydrate; colloidal anhydrous silica; behenoyl polyoxyglycerides; hydrogenated castor oil; iron oxide red - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; titanium dioxide; lactose monohydrate; colloidal anhydrous silica; hydrogenated castor oil; iron oxide yellow; medium chain triglycerides; magnesium stearate; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet, modified release - excipient ingredients: maize starch; lactose monohydrate; stearic acid; hypromellose; colloidal anhydrous silica; medium chain triglycerides; indigo carmine aluminium lake; titanium dioxide; behenoyl polyoxyglycerides; copovidone; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: titanium dioxide; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch; lactose monohydrate; magnesium stearate; hydrogenated castor oil; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: copovidone; colloidal anhydrous silica; lactose monohydrate; behenoyl polyoxyglycerides; titanium dioxide; hydrogenated castor oil; stearic acid; magnesium stearate; medium chain triglycerides; maize starch; microcrystalline cellulose; hypromellose; iron oxide black; colour - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.